BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 34,000 Shares of Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 34,000 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00. Following the sale, the chief executive officer directly owned 568,209 shares in the company, valued at approximately $54,826,486.41. This represents a 5.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Trading Down 0.9%

BioNTech stock opened at $95.83 on Thursday. The stock has a market cap of $24.23 billion, a P/E ratio of -12.24 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The firm’s 50 day moving average price is $97.17 and its 200-day moving average price is $95.00.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech’s revenue was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.60) EPS. On average, equities analysts predict that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of large investors have recently made changes to their positions in BNTX. Engineers Gate Manager LP raised its position in shares of BioNTech by 17.3% during the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after buying an additional 1,833 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of BioNTech in the 2nd quarter valued at about $39,000. Nykredit A S purchased a new position in BioNTech in the second quarter worth about $293,000. B. Metzler seel. Sohn & Co. AG grew its position in BioNTech by 66.7% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock worth $1,020,000 after acquiring an additional 4,390 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in BioNTech during the second quarter worth approximately $2,520,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. UBS Group reissued a “buy” rating on shares of BioNTech in a research note on Wednesday. Citigroup cut their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th. Finally, Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.